Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3038 Managing Neuroendocrine Neoplasms (NEN) in Association with HIV Infection: A Single Institution Experience

Introduction: There is a paucity of knowledge regarding NEN and HIV infection in the literature.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hayes A, Smith K, Liu M, Jenkinson S, Grossman A,

Keywords: Neuroendocrine, Carcinoid, Merkel cell carcinoma, Human immunodeficiency virus, HIV, Prognosis,

#1891 GSK3: A Novel Therapeutic Target in NETs?

Introduction: GSK3 is a serine/threonine-kinase that plays a critical role in cancer. In neuroendocrine tumours (NETs) GSK3 is regularly overactivated.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Nölting S

Authors: Weis C, Aristizabal Prada E, Maurer J, Spöttl G, Grossman A,

Keywords: GSK3-inhibition, neuroendocrine tumors, combination treatment,

#662 Sequlae and Survivorship in Neuroendocrine Patients Treated with 131I-MIBG

Introduction: Radionuclide therapy in the form of 131I-MIBG has been in therapeutic use since the 1980s. Newer modalities are emerging for the treatment of neuroendocrine and chromaffin cell tumors, but many of these do not yet have adequate long-term follow-up to determine longer term efficacy and sequelae.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Sze C, Grossman A, Amendra D, Shieh S, Plowman N,

Keywords: neuroendocrine tumors, chromaffin cell tumors, radionuclide therapy, survival, long-term sequelae ,

#387 Combined Blockade of Several Signalling Pathways Shows Marked Anti-Tumor Potential in Two Novel Mouse Phaeochromocytoma Cell Lines

Introduction: The current study explores novel targeted therapies for malignant pheochromocytomas (PCCs) and paragangliomas, utilizing a more benign (MPC) and a more malignant (MTT) PCC cell line. We have previously shown that the dual PI3K/mTORC1 inhibitor NVP-BEZ235 significantly reduced MPC and MTT cell viability, but increased ERK signalling.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Noelting S, Garcia E, Alusi G, Korbonits M, Grossman A,

Keywords: pheochromocytoma, cell lines, proliferation, MAPK, mTOR,

#66 Adrenocortical cancer: a therapeutic approach with everolimus (RAD001)

Introduction: Adrenocortical cancer (ACC) is a rare disease with very poor outcome. ACC responds poorly to standard chemotherapy. Mitotane, used as adjuvant therapy to surgery, prolongs recurrence-free survival, but the response is limited to 23% of patients and resistance occurs in the majority of patients (1). There is no curative therapy for ACC. Pre-clinical studies have shown involvement of both IGF-2/IGF-1R and Akt/mTOR pathways in ACC, and IGF-1R and mTOR inhibitors inhibited cell proliferation of human adrenocortical carcinoma cell lines in vitro (2,3,4).

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Gueorguiev M, Bhattacharya S, Grossman A,

Keywords: adrenocortical cancer, mTOR inhibitors, everolimus,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.